
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      or refractory CD19+ B-cell hematological malignancies, including acute lymphoblastic leukemia
      and B-cell non-Hodgkin's lymphoma. The selections of dose levels and the number of subjects
      are based on clinical trials of similar foreign products. Two groups of patients will be
      enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is
      dose- related safety.
    
  